News
JNJ
148.53
-0.69%
-1.03
Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset
Shares of Cidara Therapeutics are up 42% in after-hours trading. The company divested a candidiasis treatment to its partner and bought back the rights to an influenza-prevention treatment. The stock is up roughly 15-fold since the start of the year.
Dow Jones · 5h ago
Cidara Therapeutics Reacquires Global Development And Commercial Rights To CD388 From Johnson & Johnson For A One Time Payment Of $85M; Announces Private Placement Financing Of $240M
Cidara Therapeutics, Inc. Has entered into a definitive agreement with Johnson & Johnson to reacquire the exclusive global development and commercial rights to CD388. $240 million private placement financing led by RA Capital Management to fund Phase 2b clinical trial. CD388 is in development for the prevention of all strains of influenza A and B.
Benzinga · 7h ago
Cidara stock rallies amid $240M private placement, drug update
Shares of Cidara Therapeutics rallied 25% in post-market trading. The company announced it had reacquired rights to its antiviral drug CD388 from Johnson & Johnson. The drug is being developed as a treatment for influenza A and B. J&J also agreed to a $240M private placement of the company's stock.
Seeking Alpha · 7h ago
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
NASDAQ · 10h ago
Neurocrine Biosciences upgraded at Wells Fargo on pipeline
Wells Fargo upgraded Neurocrine Biosciences from equal weight to overweight on the strength of its pipeline. The firm also upped its price target to $170 from $140. Analyst believes the company's crinecerfont could be a $1.5B drug.
Seeking Alpha · 12h ago
Dow Movers: JNJ, BA
NASDAQ · 13h ago
The Zacks Analyst Blog Highlights KB Home, Interactive Brokers Group, Qualcomm and Johnson & Johnson
NASDAQ · 15h ago
March Readers Marked 20 Ideal-To-Buy Dividend Dogs
Home Dividends Analysis Dividend Quick Picks March Readers Marked 20 Ideal-To-Buy Dividending Dogs. Of the 32 stocks mentioned by Fly_dragonfly in their comments, 20 qualified as "ideal" for dividend-paying stocks. Two stocks made the top 20 list for the month of March.
Seeking Alpha · 18h ago
Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever
Three undervalued blue chip stocks you can buy for $5,000 or less and hold forever. Johnson & Johnson has paid and raised its dividend for 62 consecutive years. Altria Group is a tobacco company that's focusing on smokeless products. Realty Income is a great way to benefit from owning real estate.
The Motley Fool · 18h ago
Sanofi reportedly lining up banks for consumer products spinoff
Healthcare M&A Sanofi reportedly lining up banks for consumer products spinoff. French drugmaker has asked banks to submit proposals for a potential spinoff of its consumer health products division. The company is mulling whether to spin off the unit or sell it outright. A separate listing could be valued at over $20B.
Seeking Alpha · 1d ago
Baron Health Care Fund Q1 2024 Shareholder Letter
Baron Health Care Fund advanced 8.92% in the quarter ended March 31, 2024. The Fund's performance was in line with the Russell 3000 Health Care Index and the S&P 500 Index. Investments in health care equipment, pharmaceuticals, and life sciences added the most value in the period.
Seeking Alpha · 1d ago
4 Stocks to Watch on Their Recent Dividend Hikes
NASDAQ · 1d ago
Not A Millionaire? No Problem! Here's A 10-Stock Portfolio To Retire Comfortably
The retirement crisis may not be as bad as it seems, with most retirees doing fine with less savings than expected. The expected amount to retire comfortably in the United States is now north of $1.4 million. The average retirement savings for U.S. Adults is only $88,400. A low-risk portfolio consisting of dividend growth stocks can yield substantial returns in retirement.
Seeking Alpha · 1d ago
Should You Pick Abbott Stock At $105 After An Upbeat Q1?
NASDAQ · 1d ago
PPH: Buy The Pullback In This Big Pharma ETF For Long-Term Total Returns
VanEck Pharmaceutical ETF is a popular option for investors looking for exposure to leading pharmaceutical companies. The ETF's top holdings include Eli Lilly, Novo Nordisk, and Johnson & Johnson. The fund has been in an uptrend since late last year and is currently trading at a level that presents a buying opportunity.
Seeking Alpha · 1d ago
WHO no longer planning safety alert on Kenvue cough syrup: report
Healthcare WHO no longer planning safety alert on Kenvue cough syrup: report. Concerns that a batch sold in several African nations had been contaminated by the chemical diethylene glycol. The product has been pulled from shelves in Nigeria, Kenya, Rwanda, Tanzania and South Africa.
Seeking Alpha · 2d ago
Johnson & Johnson: Legal Woes Are Detrimental But Not Fatal
Johnson & Johnson stock has continued to underperform the healthcare sector. JNJ's potentially massive talc-related legal liabilities will likely affect buying sentiment. However, JNJ is a fundamentally strong business with robust free cash flow profitability. Johnson & Johnson's growth momentum in the second half is expected to be strong.
Seeking Alpha · 2d ago
Johnson & Johnson to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC)
Johnson & Johnson will participate in the Bernstein’s 40th Annual Strategic Decisions Conference on Wednesday, May 29th. Joaquin Duato, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 1:30 pm. The live audio webcast will be available on the Johnson & Johnson website.
Barchart · 2d ago
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
NASDAQ · 2d ago
PKW: Buyback ETF Combining Value And Growth
Invesco BuyBack Achievers ETF invests in companies that have reduced shares outstanding by at least 5% in the last 12 months. The portfolio massively underweights technology, and beats the benchmark regarding value, growth and return metrics. PKW: Buyback ETF Combining Value And Growth is a rare combination of value and growth.
Seeking Alpha · 2d ago
More
Webull provides a variety of real-time JNJ stock news. You can receive the latest news about Johnson & Johnson through multiple platforms. This information may help you make smarter investment decisions.
About JNJ
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, and vision fields. These products are distributed to wholesalers, hospitals, and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.